Ebrahimian Mahboubeh, Shahgordi Sanaz, Yazdian-Robati Rezvan, Etemad Leila, Hashemi Maryam, Salmasi Zahra
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Immunology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Avicenna J Phytomed. 2022 May-Jun;12(3):295-308. doi: 10.22038/AJP.2022.20022.
The aim of this study was to investigate the efficacy of mesenchyme stem cells (MSCs) derived from human adipose tissue (hMSCs) as carriers for delivery of galbanic acid (GBA), a potential anticancer agent, loaded into poly (lactic-co-glycolic acid) (PLGA) nanoparticles (nano-engineered hMSCs) against tumor cells.
GBA-loaded PLGA nanoparticles (PLGA/GBA) were prepared by single emulsion method and their physicochemical properties were evaluated. Then, PLGA/GBA nanoparticles were incorporated into hMSCs (hMSC/PLGA-GBA) and their migration ability and cytotoxicity against colon cancer cells were investigated.
The loading efficiency of PLGA/GBA nanoparticles with average size of 214±30.5 nm into hMSCs, was about 85 and 92% at GBA concentration of 20 and 40 μM, respectively. Nano-engineered hMSCs showed significant higher migration to cancer cells (C26) compared to normal cells (NIH/3T3). Furthermore, nano-engineered hMSCs could effectively induce cell death in C26 cells in comparison with non-engineered hMSCs.
hMSCs could be implemented for efficient loading of PLGA/GBA nanoparticles to produce a targeted cellular carrier against cancer cells. Thus, according to minimal toxicity on normal cells, it deserves to be considered as a valuable platform for drug delivery in cancer therapy.
本研究旨在探讨源自人脂肪组织的间充质干细胞(hMSCs)作为载体递送没食子酸(GBA,一种潜在的抗癌剂)的功效,该抗癌剂被负载于聚乳酸 - 乙醇酸共聚物(PLGA)纳米颗粒中(纳米工程化的hMSCs),用于对抗肿瘤细胞。
采用单乳液法制备负载GBA的PLGA纳米颗粒(PLGA/GBA),并评估其理化性质。然后,将PLGA/GBA纳米颗粒整合到hMSCs中(hMSC/PLGA - GBA),并研究其迁移能力和对结肠癌细胞的细胞毒性。
平均粒径为214±30.5 nm的PLGA/GBA纳米颗粒在GBA浓度为20和40 μM时,负载到hMSCs中的效率分别约为85%和92%。与正常细胞(NIH/3T3)相比,纳米工程化的hMSCs向癌细胞(C26)的迁移显著更高。此外,与未工程化的hMSCs相比,纳米工程化的hMSCs能有效诱导C26细胞死亡。
hMSCs可用于高效负载PLGA/GBA纳米颗粒,以产生针对癌细胞的靶向细胞载体。因此,鉴于其对正常细胞的毒性极小,它值得被视为癌症治疗中药物递送的一个有价值的平台。